皮下注射艾加莫德联合泼尼松治疗中重度天疱疮的III期ADDRESS试验
ADDRESS是一项全球III期随机双盲安慰剂对照试验,纳入222例新诊断或复发的中重度天疱疮成人患者,按2:1随机接受皮下艾加莫德PH20或安慰剂,均联合泼尼松。主要终点为第30周时达到最小剂量泼尼松维持完全缓解(CRmin)至少8周的PV患者比例,两组无统计学显著差异(35.5% vs 30.3%,P=0.60)。艾加莫德PH20可快速降低IgG及抗Dsg1/3抗体水平,但未转化为PDAI评分改善,安全性总体可耐受。
要点
- 皮下艾加莫德PH20联合泼尼松未显著提高第30周CRmin比例。
- 艾加莫德PH20快速降低总IgG及抗Dsg1/3抗体,但PDAI未改善。
- 两组泼尼松累积用量相当,艾加莫德组不良事件率89.1%高于安慰剂组76.0%。
核心结论
- 在中重度天疱疮患者中,皮下艾加莫德PH20联合全身糖皮质激素较单用糖皮质激素未显示30周临床获益。
- 艾加莫德PH20在该人群中耐受性良好,未出现死亡。
研究设计与样本
- 全球、III期、前瞻性、多中心、随机、双盲、安慰剂对照试验(NCT04598451)。
- 纳入222例新诊断或复发的中重度天疱疮成人患者(PV n=190,PF n=32),按2:1随机分配至艾加莫德PH20组(n=147)或安慰剂组(n=75)。
- 艾加莫德PH20第1、8天皮下2000 mg,之后每周1000 mg直至达到CRmin(泼尼松≤10 mg/日);所有患者起始泼尼松0.5 mg/kg/日。
主要发现
- PV患者第30周内达到CRmin且维持≥8周的比例:艾加莫德组44/124(35.5%)vs 安慰剂组20/66(30.3%),P=0.60,OR 1.19(95%CI 0.60-2.41)。
- 两组随时间泼尼松累积用量相当。
- 艾加莫德PH20快速降低基线总IgG及抗Dsg1、抗Dsg3自身抗体水平,但未转化为PDAI评分改善。
- 不良事件发生率:艾加莫德组89.1%(131/147)vs 安慰剂组76.0%(57/75);严重不良事件分别为12.2%(18/147)和13.3%(10/75),无死亡。
临床怎么用
- 对于中重度天疱疮,皮下艾加莫德PH20联合泼尼松在30周内未显示优于单用泼尼松的临床获益,不推荐作为常规附加治疗。
- 艾加莫德PH20虽快速降低致病抗体,但未改善疾病活动度评分,临床决策应综合评估。
局限性
- 主要终点仅针对PV患者,PF样本量较小(n=32)。
- 随访至30周,长期疗效与安全性未报告。
- 抗体水平下降未转化为临床改善的机制未阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are rare, chronic, potentially life-threatening, immunoglobulin (Ig)G-mediated, autoimmune skin and/or mucosal blistering diseases. Efgartigimod, a human IgG1 antibody Fc fragment, blocks the neonatal Fc receptor, decreasing IgG recycling and reducing both healthy and pathogenic IgG autoantibody levels. OBJECTIVES: To investigate the efficacy, safety and impact of subcutaneous efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in conjunction with prednisone in the treatment of pemphigus. METHODS: Adult participants with newly diagnosed or relapsing moderate-to-severe pemphigus were recruited in this phase III, prospective, multicentre, randomised, double-blinded, placebo-controlled study (NCT04598451). Participants were randomised (2 : 1) to weekly subcutaneous efgartigimod PH20 or placebo. Subcutaneous efgartigimod PH20 2000 mg was administered on days 1 and 8, followed by 1000 mg weekly until complete remission on minimal prednisone therapy (CRmin) (≤ 10 mg daily). All participants received concomitant prednisone starting at 0.5 mg kg-1 daily. The primary outcome was the proportion of participants with PV who achieved CRmin by week 30, while receiving minimal prednisone, for ≥ 8 weeks. Pharmacodynamics and safety were also assessed. RESULTS: Overall, 222 participants (PV: n = 190; PF: n = 32) were randomised (subcutaneous efgartigimod PH20: n = 147; placebo: n = 75). The proportions of participants with PV achieving CRmin within 30 weeks were comparable between the subcutaneous efgartigimod PH20 and placebo groups, with no statistically significant difference observed [44/124 (35.5%) vs. 20/66 (30.3%); P = 0.60; odds ratio 1.19 (95% confidence interval 0.60-2.41)]. Total prednisone consumption over time was comparable between groups. Subcutaneous efgartigimod PH20 resulted in rapid reductions from baseline in total IgG and anti--desmoglein-1 and anti-desmoglein-3 autoantibody levels, but these did not translate to improvements in Pemphigus Disease Area Index scores. The rates of adverse events (AEs) in the subcutaneous efgartigimod PH20 and placebo groups were 89.1% (n = 131/147) and 76.0% (n = 57/75), respectively; most were mild to moderate [serious AEs: 12.2% (n = 18/147) and 13.3% (n = 10/75), respectively]. No deaths occurred. CONCLUSIONS: Subcutaneous efgartigimod PH20 in combination with systemic corticosteroids did not demonstrate clinical benefit over systemic corticosteroids alone in patients with moderate-to-severe pemphigus at 30 weeks, but it was well tolerated in this patient population. Pemphigus (pronounced pem–fuh–guhs) is a group of rare skin conditions. These can cause painful blisters and sores. Pemphigus occurs when the body’s immune system mistakenly makes disease-causing antibodies. These antibodies attack proteins that bind skin cells together. Without treatment, pemphigus can be fatal. The ADDRESS trial included adults at 82 study sites across 20 countries. We tested a drug called efgartigimod for safety and efficacy in pemphigus. Efgartigimod is made from a piece of antibody, which binds to a protein called ‘FcRn’. FcRn helps maintain antibody levels. By binding FcRn, efgartigimod acts to reduce antibodies. This includes the antibodies that attack the body in pemphigus. Over 30 weeks, we examined how many people given efgartigimod had 8 weeks of no symptoms. We compared that number with the number of people who had been given a ‘placebo’ who had 8 weeks of no symptoms. The placebo looks like efgartigimod but does not affect antibody levels. Both groups were also given another drug called prednisone. We found that around one-third of people in each group had an 8-week symptom-free period. Around 9 in 10 people given efgartigimod experienced ‘adverse events’. This compares with 7.6 in 10 people given placebo. Most of these adverse events were mild or moderate and went away after a few days or were treated. About every eighth patient in each group had serious adverse events. These could be life-threatening, require long hospital stays or result in long-term disability. There were no deaths during the study. This study provides useful information for future clinical trials in these complicated conditions.
引用
- Joly P, Murrell DF, Aoyama Y, et al. Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial. Br J Dermatol. 2026. PMID: 42723554. doi:10.1093/bjd/ljag199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。